Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. - Wikidata - awgldk - TriplyDB

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.

http://www.wikidata.org/entity/Q35841464

about

The Cost Effectiveness of LAA Exclusion Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective.LOWERING THE RISK FOR THROMBUS AND STROKE IN ATRIAL FIBRILLATION PATIENTS: Will Dabigatran Replace Warfarin?Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models.Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model.Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany.Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.Newer anticoagulants for non-valvular atrial fibrillation.Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.New oral anticoagulants for atrial fibrillation: are they worth the risk?Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.Role of new drugs for management of atrial fibrillation.The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation.Expanding role of pharmacogenomics in the management of cardiovascular disorders.Novel oral anticoagulants for atrial fibrillation.Almanac 2013: cardiac arrhythmias and pacing.Potential use of NOACs in developing countries: pros and cons.Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review.Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective.Implementing Guidelines: The Cost and Clinical Impact of Anticoagulants in the UK Atrial Fibrillation Population.Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department.Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation.Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.Anticoagulation for noncardiac indications in neurologic patients: comparative use of non-vitamin k oral anticoagulants, low-molecular-weight heparins, and warfarin.

P2860

Q28072579-64C0AA2D-CBAE-4695-8CE0-D895E614C1B1 Q28087146-DBE38B4D-EE5B-4AF2-8A01-F950B3467036 Q28484289-AB5CA55A-8C95-47AB-A919-8004D37E964E Q30598904-E62ECD0C-719D-4A1E-AF8D-6DB666C902BF Q34099930-3FE3FCE2-1E14-47F5-A2D0-46521E5BA826 Q34223524-8A60472C-9DEB-4451-A3B2-D498527A134A Q34604533-35B44420-9994-4E9B-8B4C-4FE45E5F8B83 Q34692850-A546943B-EB4B-4467-BA90-167AC0CB5797 Q34834319-A07BC6C5-849F-4264-A995-266489E9AD59 Q35234175-54909E6D-6E53-49B8-97B8-C0392F3E2F9C Q36841028-F7D6D1AB-5AAD-4EB1-B39B-F7235DD90B19 Q36952091-050E47EF-91C6-48C2-954D-D1A66FDC6C3A Q37083546-E2DC549C-8C26-4F2F-BA58-3BA2B050126A Q37108889-F632A7C0-AB82-4543-B1AA-0E0D1C3FC17C Q37148738-7127220F-5188-47FD-97DD-54E9A39BBD12 Q37251490-E218FFD0-9361-4694-989E-BF2CD7EBCFB2 Q37641289-61EEFBD1-B70E-4692-8BD6-FEE5FA37339A Q38021821-9038D18E-7477-4F3E-830F-8CBC83B1DB11 Q38042441-F8E969F8-08F2-4FF7-B03B-9FC421D928B8 Q38061141-D623D18F-9A0A-4367-87C9-32C70C6D0AE5 Q38068295-EA870D28-75E1-46BA-B144-7161BC47133E Q38097972-E8B5AF1C-F07F-4F85-97AB-F00A95AE2FF9 Q38098452-A016F585-0991-4FE8-BB48-A1E74BEE3E1B Q38114002-80EB9F3B-E991-4BB2-B7DA-359C70870147 Q38125860-6F98F9F5-6533-4A6C-8C4E-EB92BBF466F3 Q38210994-DE9E467B-FD10-4903-A917-6B32D0E8D7F6 Q38236215-B49A0810-12AC-4831-95D2-EC4CB71D2FDF Q38713953-C1AC6FD3-4B78-44EB-AE09-B435CC508071 Q39096950-8E18C68D-995C-4057-8137-6D3F4205030D Q39325539-BC9FA860-987B-48CD-9031-77D828F97C6C Q40832438-0C8FD1D0-B647-482E-B0AD-1E8EC07D6DCB Q42924723-C8970626-A21C-42EA-9550-D3F2839CF5A5 Q44700478-E45850D2-F3D4-4DE7-8B30-A1A4459BFD03 Q46663237-F8940109-F0AF-40F6-9DE8-CE234E62A5A7 Q47142865-E2034E36-96D3-4677-A414-432B1830C169 Q47448340-504E5E92-C9A5-4C03-B676-F37508B1F52D

P2860

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.

http://www.wikidata.org/entity/Q35841464

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Cost-effectiveness of dabigatr ...... ents with atrial fibrillation.

@ast

Cost-effectiveness of dabigatr ...... ents with atrial fibrillation.

@en

type

label

Cost-effectiveness of dabigatr ...... ents with atrial fibrillation.

@ast

Cost-effectiveness of dabigatr ...... ents with atrial fibrillation.

@en

prefLabel

Cost-effectiveness of dabigatr ...... ents with atrial fibrillation.

@ast

Cost-effectiveness of dabigatr ...... ents with atrial fibrillation.

@en

P1433

Q35841464-953563E0-B8D5-4B89-B417-806E7372834E

P1476

Q35841464-7FC2BBEB-BCDC-41CA-8A13-68D2997493E1

P2093

Q35841464-08DF4622-401F-4BD4-A727-CBFC70B61756

Q35841464-232DE2F3-6556-4C2B-BA3F-33679200FB9A

Q35841464-307B4A4D-2ABD-4007-B3F0-B818B791EA76

Q35841464-75A47A95-D295-47B6-9140-90B6BFFD4275

Q35841464-81D52AEC-39EE-44A0-B0AA-21FCC0AD788F

Q35841464-92797B43-5B33-48F7-8DC6-5919F97ED7CB

P2860

Q35841464-072A0039-E70C-4E3E-AFC4-05ECEFF8AD90

Q35841464-25B8BC62-F423-49F7-86BC-FE07567CF409

Q35841464-3193964C-0419-48C6-A1A9-5D04A53ABAF3

Q35841464-3A78CD2E-6DFE-4684-9F59-E9D536DC2C94

Q35841464-3BDACA3C-90B4-4144-A0DD-C7876D0BADAC

Q35841464-477B3B8C-3868-4DF0-BBF0-217C43402C03

Q35841464-50342867-D806-4485-BC6C-7D80D5DE2782

Q35841464-71120D26-9436-40EB-928E-78618B3D8677

Q35841464-84A20855-88CD-432F-9C86-44CC2A6A329C

Q35841464-902676BA-C4ED-4906-B268-3091CE0082CB

P304

Q35841464-306D335B-123F-4B1A-94E0-0E1CA96A35F4

P31

Q35841464-C8E498C8-8306-42EA-9582-34AAF613E22D

P356

Q35841464-3BAC6CD9-FB83-436C-BD2B-6D7FFEE08199

P407

Q35841464-4E5708EE-1F53-48C6-8B4D-50C2AE8FA855

P433

Q35841464-827E8580-695A-421F-9716-FBEDA4A9D5E5

P478

Q35841464-3D4D7696-51B2-475E-8AFA-B3E73A7CE3A4

P50

Q35841464-055C9CAE-A0F9-4415-A792-3E03837A4E50

P577

Q35841464-7C86B643-BC50-4F90-AB48-CD97DD80BE3E

P5875

Q35841464-30BD5598-7F24-4D59-85CB-B9990DA0D41D

P698

Q35841464-7C2842AC-99DD-4D4D-A995-3F534892AA9A

P921

Q35841464-6F376CF4-3C70-4B76-B72E-77D66354B14F

Q35841464-9466096A-65AB-4630-9764-CB6ECEA36495

P932

Q35841464-5A9EF73A-D9C5-4EE8-A822-F2C2BD3A8AE3

P356

HEARTJNL-2011-300646

P1433

P1476

Cost-effectiveness of dabigatr ...... ents with atrial fibrillation.

@en

P2093

Anuraag R Kansal

http://www.w3.org/2001/XMLSchema#string

Feng Pan

http://www.w3.org/2001/XMLSchema#string

Jonathan M Plumb

http://www.w3.org/2001/XMLSchema#string

Paul Robinson

http://www.w3.org/2001/XMLSchema#string

Ray Gani

http://www.w3.org/2001/XMLSchema#string

Sonja V Sorensen

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US

Dabigatran versus warfarin in patients with atrial fibrillation

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care.

Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?

Effect of study setting on anticoagulation control: a systematic review and metaregression.

Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

P304

573-578

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/HEARTJNL-2011-300646

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221965253

http://www.w3.org/2001/XMLSchema#string

P698

22422743

http://www.w3.org/2001/XMLSchema#string

P921

dabigatran etexilate

atrial fibrillation

P932

3308473

http://www.w3.org/2001/XMLSchema#string